ASHAMARAH HEATH: Open Payments
NPI 1730810912 · HOUSTON, TX. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$1,100 in 24 payments from 12 companies in 2025. Trend: 2023 $311 · 2024 $1,237 · 2025 $1,100
Food & beverage: $1,100
| Company | Payments | Amount |
|---|---|---|
| AstraZeneca Pharmaceuticals LP | 3 | $231 |
| Merck Sharp & Dohme LLC | 5 | $222 |
| GlaxoSmithKline, LLC. | 2 | $157 |
| ABBVIE INC. | 2 | $153 |
| Baxter Healthcare | 1 | $98 |
| Caris MPI, Inc. | 3 | $63 |
| Eisai Inc. | 2 | $51 |
| Genmab U.S., Inc. | 2 | $41 |
| Davol Inc. | 1 | $23 |
| Myriad Genetic Laboratories, Inc. | 1 | $22 |
Products named: LYNPARZA, ELAHERE, KEYTRUDA, ZEJULA, TISSEEL, MI CANCER SEEK, Lenvima, Tivdak.
Industry payments across TX — which companies pay providers there.
